Does anyone take ADHD stimulant meds (Adderall, Vyvanse)? Tips on reducing neurotoxicity risk?

Found a good series on ADHD stimulants and how to optimize their usage to minimize side effects:

Key actionable points from all 3 videos:

1. Use the Lowest Effective Dose

  • Stay around 5 to 10 mg.
  • Avoid dose escalation.
  • Never chase euphoria.

2. Prefer Short-Acting Formulations

  • Avoid extended release if it disrupts sleep or keeps adrenaline elevated.
  • Let your nervous system fully reset each day.

3. Take Regular Off Days

  • Use stimulants 4 to 5 days per week max.
  • Take at least 2 consecutive days off.
  • Preserve dopamine sensitivity.

4. Pair Medication With High-Value Work

  • Only use during difficult, meaningful tasks.
  • Do not pair with entertainment or low-value dopamine activities.
  • Train focus so you eventually need less medication.

5. Enhance Dopamine Efficiency, Not Dose

  • Consider strategies that prolong dopamine action rather than increase release.
  • Avoid stacking multiple dopamine-releasing agents.

6. Address Other ADHD Mechanisms

  • Investigate anxiety, glutamate excess, GABA imbalance, histamine, or cholinergic issues if dopamine targeting is insufficient.

7. Support Neural Health

  • Avoid chronic sympathetic overdrive.
  • Monitor cardiovascular stress.
  • Protect sleep and circadian rhythm.
  • The speaker argues that higher doses of amphetamine medications are not better and recommends keeping Adderall at a low dose (around 5 mg, never above about 10 mg) to avoid dopamine receptor downregulation and excessive sympathetic nervous system activation.
  • He prefers dextroamphetamine-dominant formulations because they are more dopaminergic and less adrenergic than equal-salt generics, which may reduce stress and side effects.
  • He stresses the importance of off days (several days per week without use) to maintain effectiveness and prevent tolerance.
  • A core part of his “biohack” is to boost dopaminergic effects through receptor modulation rather than increasing the stimulant dose.
  • To achieve this, he mentions sigma-1 receptor agonism (e.g., via certain supplements or drugs like DHEA, donepezil, fluvoxamine) to potentially enhance dopaminergic signaling without more amphetamine.
  • He discusses monoamine oxidase B inhibitors, especially safinamide, as a way to prolong dopamine activity and reduce glutamatergic excitotoxicity, which he believes could make low-dose Adderall more effective and less damaging.
  • Donepezil, due to its cholinergic and sigma-1 activity, is suggested as another agent to possibly augment focus and memory when paired with low-dose amphetamines.
  • He touches on ghrelin receptor agonism (e.g., via MK-677) as another modulator of dopaminergic tone and mentions concerns about dopamine excitotoxicity, arguing that supporting plasticity and growth factors may mitigate long-term harm.
  • Additional experimental points include blocking excitatory pathways (such as glutamate) and using angiotensin receptor blockers to limit vascular and neural stress.
  • Overall, his approach frames stimulant use as a tool to accelerate learning and habituation, with an emphasis on maintaining sensitivity, protecting neurons, and enhancing dopamine efficiency rather than increasing dose.
  • The creator frames ADHD not as a disease but as a behavioral and likely polygenic phenotype involving multiple neurotransmitter systems affecting focus, memory, and attention.
  • Traditional treatments include cognitive behavioral therapy and stimulants. Stimulants like amphetamines and methylphenidate boost dopaminergic and adrenergic signaling to improve motivation and energy.
  • The video’s author prefers short-acting stimulants over extended-release versions to avoid circadian disruption and long-term side effects on sleep and nervous system regulation.
  • He recommends taking regular breaks from stimulant use (for example four to five days per week) to prevent tolerance from developing and reduce neurochemical down-regulation.
  • ADHD symptoms can arise from multiple neurobiological mechanisms, including anxiety, excess glutamate, GABA dysregulation, and histamine or cholinergic signaling issues, meaning dopamine-focused treatment does not address all cases.
  • The speaker discusses supplement and drug strategies targeting the cholinergic system, including acetylcholinesterase inhibitors and other agents thought to support memory and focus.
  • He emphasizes careful dosing of stimulants, advocating for the lowest effective dose (for example around 5-10 mg) and warning against high doses that may harm neural health.
  • Training while medicated should be purposeful: use periods of enhanced focus for valuable, difficult tasks rather than low-value activities to habituate productive behavior.
  • The video asserts that long-term stimulant use, when managed responsibly, can lead to lasting improvements in focus and cognitive function even after discontinuation.
  • Cardiovascular and stress-related side effects are a concern with long-term stimulant use, and lifestyle strategies or adjunctive medications may be needed to manage these effects.
  • Dopamine drives motivation, reward, habit formation, focus, and ambition, but excessive stimulation can lead to addiction, tolerance, and receptor downregulation.
  • The speaker warns that high daily stimulant doses, such as 50 to 70 mg of amphetamine, constitute misuse and increase long term neuroadaptation risk.
  • Dopamine signaling can be manipulated at three main points: increasing release, blocking reuptake, and inhibiting enzymatic breakdown.
  • Amphetamine increases dopamine release and also inhibits reuptake, but direct release is considered the most addictive and tolerance forming mechanism.
  • Bupropion blocks the dopamine transporter, prolonging dopamine’s action without strongly increasing release.
  • Safinamide inhibits MAO-B, slowing dopamine degradation in the extracellular space and modestly increasing dopamine tone.
  • The proposed strategy is to use a low dose stimulant and enhance its effect through reuptake and degradation inhibition instead of escalating stimulant dosage.
  • He recommends limiting stimulant use to about 4 to 5 days per week to reduce tolerance and preserve effectiveness.
  • The overall goal is to maintain cognitive enhancement while minimizing receptor downregulation, addiction risk, and dose escalation.
1 Like

Just sharing an article about the 3 types of ADHD.
I would be biotype 3.

http://archive.today/mD5E2

1 Like
1 Like

I’ve been trialling dexamphetamine for a little over 1 week so far. It can help a little bit sometimes with focus and some of the symptoms of ADHD but I overwhelmingly feel quite bad on it. I feel nauseous and less motivated at least half of the time.

Doesn’t seem sustainable for daily use, more for occasional. It is good for work, but if I use it every time I’m at work then I’ll use it often enough that there would be dependence and withdrawal if I don’t use it when not working.

I’m thinking about Vyvance for regular days and only use the dex as a bit of a top up at work if needed.

There do seem to be a lot of medication options and combos to trial.

My body seems to be a bit more used to it and I’m getting more positive effects.

Something I read about was that taking vitamin C with medication is not advised because it increases secretion of it from the body. My thought is this could be a good thing to have after your last dose to make it leave the body faster which could improve sleep.

The actual mechanism is that acidic urinary PH causes more clearance of amphetamines vs alkaline. Vitamin C doesn’t reliably increase urine PH significantly but it is a little bit. I’m going to try taking some vitamin C in the evening and see how this goes.

1 Like
2 Likes

A great article worth reading for anyone using or thinking of using ADHD stimulant medication.

The best actionable things to use as an ancillary to ADHD stimulant medication use appear to be:

2 Likes

And here’s the really direct hit — there’s a knockout mouse study with d-amphetamine specifically:

In NQO1-deficient mice, d-amphetamine-induced psychomotor activity and psychological dependency were both increased compared to wild-type mice. Basal and d-amphetamine-induced dopamine levels were also enhanced by NQO1 deficiency, with higher neural activation in the dorsolateral striatum PubMed. And it gets weirder: the rewarding effect in response to D1 agonist was increased by NQO1 deficiency PubMed. So NQO1 knockout mice are both more sensitive to amphetamine’s rewarding effects AND presumably accumulating more dopamine quinone without the enzymatic machinery to handle it.

That’s a nasty combination — enhanced dopaminergic response (more DA release, more reward) coupled with reduced ability to detoxify the oxidative byproducts of that enhanced response. More fuel and less fire suppression simultaneously.

Oxidative stress plays an important role in the mechanisms of METH dependence neurotoxicity — METH intake causes dopamine release and then produces dopamine-quinones and additional reactive oxygen species by auto-oxidation Wiley Online Library. And the epidemiological data supports the genetic link: the T allele and T-carrying genotypes of NQO1 609C/T were associated with increased susceptibility to METH dependence Wiley Online Library.

Now — d-amphetamine vs methamphetamine, and dose matters a lot here

I want to flag my uncertainty on how directly this translates to therapeutic-dose amphetamine (Adderall/Vyvanse) vs. the neurotoxic binge doses used in rodent METH studies. The METH neurotoxicity literature mostly uses doses designed to produce frank terminal degeneration — that’s a different regime than 20mg of mixed amphetamine salts daily. The dopamine quinone pathway scales with the amount of cytosolic dopamine overflow, so:

  • Therapeutic doses: Some dopamine quinone formation, probably modest. NQO1 deficiency means slightly less cleanup. I’d put this at “plausible mild additional oxidative burden” (~0.4 confidence it’s clinically meaningful at normal doses).

==

  • Take ubiquinol rather than ubiquinone as your CoQ10 form. The theoretical rationale is that you can’t efficiently reduce ubiquinone to ubiquinol via NQO1 in the plasma membrane. This is the one intervention that directly patches the missing enzyme. (~0.6 confidence it matters, low downside.)
1 Like

I’ll anchor this to 5 mg Adderall per use, because otherwise the model becomes a choose-your-own-neurochemistry pamphlet, and those are how civilization collapses.

A 5 mg Adderall tablet is 3.13 mg total amphetamine base equivalent, not 5 mg pure amphetamine base. DailyMed lists the 5 mg tablet as four 1.25 mg amphetamine salts and gives 3.13 mg total amphetamine base equivalence. So if you mean 5 mg pure AMPH base, multiply my Adderall-table numbers by ~1.6. If you mean 10 mg Adderall, double them. (DailyMed)

Also: P187S can mean heterozygous or homozygous. NQO1 C609T / P187S strongly reduces NQO1 protein stability; homozygous variant is reported around 2–4% of WT activity, while heterozygotes have roughly threefold lower activity than WT. I’ll show both, because apparently genetics decided one ambiguity was not enough. (Nature)

Model constants I’m using

From the prior model, converted to 5 mg Adderall = 3.13 mg AMPH base equivalent:

NQO1 state Added protein adducts per 5 mg Adderall use Event count True crosslink-like events per use Event count
Normal NQO1 ~1.13 pmol ~6.8 × 10¹¹ ~0.00338 pmol ~2.0 × 10⁹
P187S heterozygous ~2.25 pmol ~1.36 × 10¹² ~0.00676 pmol ~4.1 × 10⁹
P187S homozygous ~4.51 pmol ~2.71 × 10¹² ~0.0135 pmol ~8.1 × 10⁹

These are residue-hit / adduct events, not “unique proteins permanently destroyed.” Many damaged proteins are degraded, replaced, repaired indirectly, or sequestered. Tiny mercy from the protein-quality-control machinery, which for once is doing its job.

Dopamine oxidation does plausibly make protein adducts: dopamine o-quinone can form adducts with proteins including DAT, DJ-1, UCHL-1, mitochondrial proteins, glutathione peroxidase-4, and tyrosine hydroxylase; dopamine o-quinone also rapidly cyclizes toward aminochrome, and aminochrome has been linked to mitochondrial dysfunction, ER stress, autophagy/proteasome dysfunction, oxidative stress, and α-synuclein oligomer formation. (Frontiers)

5-year integrated totals, 5 mg Adderall per use

Protein adduct events over 5 years

Use rate Normal NQO1 P187S heterozygous P187S homozygous
5 days/year, 25 uses ~28.2 pmol, ~1.70 × 10¹³ events ~56.3 pmol, ~3.39 × 10¹³ events ~113 pmol, ~6.79 × 10¹³ events
10 days/year, 50 uses ~56.3 pmol, ~3.39 × 10¹³ events ~113 pmol, ~6.79 × 10¹³ events ~225 pmol, ~1.36 × 10¹⁴ events
90 days/year, 450 uses ~507 pmol, ~3.05 × 10¹⁴ events ~1.01 nmol, ~6.11 × 10¹⁴ events ~2.03 nmol, ~1.22 × 10¹⁵ events

Crosslink-like events over 5 years

Use rate Normal NQO1 P187S heterozygous P187S homozygous
5 days/year ~0.0845 pmol, ~5.09 × 10¹⁰ events ~0.169 pmol, ~1.02 × 10¹¹ events ~0.338 pmol, ~2.04 × 10¹¹ events
10 days/year ~0.169 pmol, ~1.02 × 10¹¹ events ~0.338 pmol, ~2.04 × 10¹¹ events ~0.676 pmol, ~4.07 × 10¹¹ events
90 days/year ~1.52 pmol, ~9.16 × 10¹¹ events ~3.04 pmol, ~1.83 × 10¹² events ~6.08 pmol, ~3.66 × 10¹² events

So for P187S heterozygous, 5 years of 5 mg Adderall at 90 days/year lands around:

~1.0 nmol protein adduct events and ~3 pmol crosslink-like events.

For P187S homozygous, same pattern:

~2.0 nmol protein adduct events and ~6 pmol crosslink-like events.

That sounds enormous in molecule-count terms because Avogadro’s number exists mainly to make humans feel doomed. In tissue-scale terms, it is still small, but locally in dopaminergic terminals it could be less small.

What MPH taken along with it probably does

Mechanistically, amphetamine and methylphenidate are not equivalent. Amphetamine can enter neurons via DAT and diffusion, interacts with VMAT2, increases cytosolic dopamine, and drives dopamine efflux. Methylphenidate mainly blocks DAT/NET reuptake and alters catecholamine availability differently. (ScienceDirect)

For quinone/adduct load, that matters:

Scenario Estimated effect on adduct burden relative to Adderall alone
5 mg Adderall alone 1.00×
5 mg Adderall + low/moderate oral MPH same day central ~1.25×
Plausible acute range ~0.8–2.0×
Chronic/high-dose MPH exposure before AMPH possibly ~1.3–2.5×, but this is much shakier

Why the range is annoying: MPH increases extracellular dopamine, which could increase oxidation/adduct pressure, but by occupying DAT it may also partially reduce amphetamine entry through DAT in some timing windows. Chronic/high-dose MPH self-administration in rats increased DAT levels and enhanced amphetamine potency, but that is not the same as careful prescribed oral use in a 46 kg human. (Nature)

Using the central 1.25× multiplier for Adderall + MPH, the 5-year P187S estimates become:

Use rate P187S heterozygous adducts with MPH P187S homozygous adducts with MPH
5 days/year ~70.4 pmol, ~4.24 × 10¹³ events ~141 pmol, ~8.48 × 10¹³ events
10 days/year ~141 pmol, ~8.48 × 10¹³ events ~282 pmol, ~1.70 × 10¹⁴ events
90 days/year ~1.27 nmol, ~7.64 × 10¹⁴ events ~2.54 nmol, ~1.53 × 10¹⁵ events

Crosslinks scale the same way:

Use rate P187S heterozygous crosslinks with MPH P187S homozygous crosslinks with MPH
5 days/year ~0.211 pmol, ~1.27 × 10¹¹ events ~0.423 pmol, ~2.54 × 10¹¹ events
10 days/year ~0.423 pmol, ~2.54 × 10¹¹ events ~0.845 pmol, ~5.09 × 10¹¹ events
90 days/year ~3.80 pmol, ~2.29 × 10¹² events ~7.61 pmol, ~4.58 × 10¹² events

This is not a recommendation to combine them. Adderall’s label explicitly says co-medications should be handled by a healthcare provider, and stimulants carry cardiovascular, psychiatric, misuse, and interaction risks. Tiny detail, but organs do enjoy not being surprised. (DailyMed)

Lifetime side-by-side: normal NQO1 vs P187S

For “lifetime,” I’ll use 60 years of the same use pattern. Multiply by 0.5 for 30 years, 1.33 for 80 years, etc.

Lifetime protein adduct events, 5 mg Adderall per use, no MPH

Use rate Normal NQO1 P187S heterozygous P187S homozygous
5 days/year, 300 lifetime uses ~338 pmol, ~2.04 × 10¹⁴ events ~676 pmol, ~4.07 × 10¹⁴ events ~1.35 nmol, ~8.14 × 10¹⁴ events
10 days/year, 600 uses ~676 pmol, ~4.07 × 10¹⁴ events ~1.35 nmol, ~8.14 × 10¹⁴ events ~2.70 nmol, ~1.63 × 10¹⁵ events
90 days/year, 5,400 uses ~6.08 nmol, ~3.66 × 10¹⁵ events ~12.17 nmol, ~7.33 × 10¹⁵ events ~24.34 nmol, ~1.47 × 10¹⁶ events

Lifetime crosslink-like events, 5 mg Adderall per use, no MPH

Use rate Normal NQO1 P187S heterozygous P187S homozygous
5 days/year ~1.01 pmol, ~6.11 × 10¹¹ events ~2.03 pmol, ~1.22 × 10¹² events ~4.06 pmol, ~2.44 × 10¹² events
10 days/year ~2.03 pmol, ~1.22 × 10¹² events ~4.06 pmol, ~2.44 × 10¹² events ~8.11 pmol, ~4.89 × 10¹² events
90 days/year ~18.3 pmol, ~1.10 × 10¹³ events ~36.5 pmol, ~2.20 × 10¹³ events ~73.0 pmol, ~4.40 × 10¹³ events

With MPH co-use using the central 1.25× multiplier, multiply every lifetime number above by 1.25. So the highest listed case, P187S homozygous + 90 days/year for 60 years, becomes roughly:

~30.4 nmol protein adduct events and ~91 pmol crosslink-like events.

When would this meaningfully impair dopamine signaling?

Here’s the part where precision goes to die in a swamp wearing a lab coat.

The best answer is: with functioning protein turnover, probably not within a normal human lifespan at 5–10 days/year, and likely not from quinone adduct burden alone even at 90 days/year. The bigger realistic concerns are acute physiology, sleep loss, blood pressure/heart rate, psychiatric side effects, dose escalation, oxidative stress background, and whether the drug is actually helping you function.

Why cumulative events are not cumulative damage: neuronal proteins turn over. One synaptic-protein study found many synaptic proteins with half-lives around 2–5 days, broader reviews put neuronal/synaptic protein half-lives from days to weeks, sometimes months, and a 2025 review of human iPSC-derived dopaminergic neurons reported a median protein half-life around 97 hours. (PMC)

To force a number anyway, I’ll define 90% dopamine-signal carrying ability as:
persistent functional damage reaching ~10% of the DAT-equivalent dopamine-signaling machinery in striatum.

Human striatal DAT binding density has been reported around 56.8–147.7 pmol/g tissue depending on method/region, so a whole-striatum DAT-equivalent pool is plausibly on the order of ~1–2 nmol, making a 10% impairment threshold roughly ~100–200 pmol of persistent critical damage. This is a crude anchor, not a holy tablet delivered from Mount Dopamine. (PubMed)

Realistic turnover model

If adducted proteins are cleared with half-lives of days to weeks, then even the high case, 5 mg Adderall, 90 days/year, P187S homozygous, gives a steady-state critical-damage pool far below the ~100–200 pmol threshold unless several pessimistic things are true at once:

  • adducts are highly concentrated onto dopamine-signal-critical proteins,
  • clearance/autophagy/proteasome function is impaired,
  • oxidative stress/GSH buffering is poor,
  • crosslinked/oligomeric material persists for years,
  • exposure is higher than 5 mg Adderall or much more frequent than 90 days/year.

Central estimate under functioning turnover: you do not hit a 10% dopamine-signal deficit threshold from this adduct mechanism alone.

No-clearance worst-case thought experiment

Now suppose, unrealistically, that 1% of all adduct events hit dopamine-signal-critical machinery and persist indefinitely. This is intentionally pessimistic. Under that model, the time to reach a ~150 pmol critical-damage threshold is:

Use rate, 5 mg Adderall Normal NQO1 P187S heterozygous P187S homozygous
5 days/year ~2,660 years ~1,330 years ~666 years
10 days/year ~1,330 years ~666 years ~333 years
90 days/year ~148 years ~74 years ~37 years

With central MPH co-use, divide those times by ~1.25:

Use rate, Adderall + MPH Normal NQO1 P187S heterozygous P187S homozygous
5 days/year ~2,130 years ~1,065 years ~533 years
10 days/year ~1,065 years ~533 years ~266 years
90 days/year ~118 years ~59 years ~30 years

If 5% of adducts hit critical dopamine machinery and persist, divide those year estimates by 5. If only 0.1% do, multiply them by 10. Biology, naturally, refuses to file the relevant paperwork.

Practical bottom line

For 5 mg Adderall, 5–10 days/year looks chemically tiny in this model, even with P187S.

For 90 days/year, central 5-year estimates are approximately:

State Protein adducts over 5 years Crosslink-like events over 5 years
Normal NQO1 ~507 pmol ~1.52 pmol
P187S heterozygous ~1.01 nmol ~3.04 pmol
P187S homozygous ~2.03 nmol ~6.08 pmol
P187S homozygous + MPH central ~2.54 nmol ~7.61 pmol

My best estimate for the “when do I fall to 90% dopamine signaling?” question:

At 5–10 Adderall-use days/year: not from this mechanism within a human lifespan.
At 90 days/year: likely still not from adduct accumulation alone if proteostasis is normal; pessimistic no-clearance modeling gives ~60–75 years for P187S heterozygous, ~30–40 years for P187S homozygous, and ~25–60 years if MPH pushes the burden upward.

The true risk is probably less “your proteins gradually become a crosslinked graveyard” and more “local vulnerable proteins get selectively hit during bad metabolic states.” Sleep loss, inflammation, iron/copper load, low GSH, mitochondrial stress, high dose, binges, and poor recovery days matter more than the clean little linear table. Annoying, but at least accurate.

1 Like

Yes. The threshold model should be spatial, not just “total molecules over lifetime.” The important result is:

dopamine-o-quinone basically does not travel long-range inside neurons. Aminochrome can spread locally, maybe tens of microns. H₂O₂ is the only one of the three that plausibly travels across local microdomains or neighboring cells.

So the badness is not “quinones made near soma diffuse to distal axons/spines and ruin the place like tiny biochemical tourists.” They mostly react near where they are made. Distal boutons get hit because they generate their own load locally, not because toxins diffuse there from proximal neuron parts. A rare moment where the universe is less bad than feared, though naturally it chose a more complicated way to be less bad.

1. Transport model

For each species, model concentration along an axon/dendrite as:

[
\frac{\partial C}{\partial t}

D\nabla^2C

v\nabla C

kC
+
S(x,t)
]

where:

Term Meaning
(D) diffusion coefficient
(v) advective/axoplasmic flow velocity
(k) effective first-order removal/reaction rate
(S(x,t)) local production from dopamine oxidation / MAO / mitochondria

For a local source, the decay length is approximately:

[
L \approx \sqrt{\frac{D}{k}}
]

If advection matters:

[
L_{\text{downstream}}

\frac{2D}{\sqrt{v^2+4Dk}-v}
]

But for free dopamine-o-quinone and aminochrome, advection is usually a rounding error wearing a lab coat. Free reactive small molecules are not shipped neatly down axons by kinesin like cargo vesicles. They diffuse and react. Fast axonal transport moves organelles/proteins, not loose quinones.

2. Parameter estimates

Dopamine diffusion in brain/extracellular settings is often estimated around 0.6–2 × 10⁻⁶ cm²/s, while dopamine in water is around 6 × 10⁻⁶ cm²/s. That converts roughly to 60–600 μm²/s, so for cytosolic dopamine-o-quinone/aminochrome I’ll use ~200 μm²/s as a reasonable middle estimate. H₂O₂ is more mobile; measured effective brain-tissue H₂O₂ diffusivity was reported as 2.5 × 10⁻⁵ cm²/s, or ~2500 μm²/s, and intracellular H₂O₂ can still be sharply shortened by peroxiredoxin/GPx scavenging. (PMC)

Dopamine-o-quinone cyclizes to aminochrome at about 0.15 s⁻¹ at physiological pH if nothing else grabs it, but in real cytosol it competes with GSH, cysteine residues, protein thiols, GSTM2, NQO1/DT-diaphorase, and other nucleophiles. Dopamine-o-quinone can form adducts with proteins including DAT, DJ-1, UCHL-1, mitochondrial proteins, GPx4, and tyrosine hydroxylase; aminochrome is linked to mitochondrial dysfunction, ER stress, proteasome/autophagy dysfunction, oxidative stress, and α-synuclein oligomerization. (PMC)

3. How far do these species travel before reacting?

Central estimates:

Species Effective lifetime Diffusion length (L) Practical interpretation
Dopamine-o-quinone, normal cytosol ~1–50 ms ~0.5–5 μm Mostly reacts inside/near the bouton, spine, or local shaft where it forms
Dopamine-o-quinone, only cyclization considered ~6.7 s mean lifetime ~35–40 μm Unrealistically permissive because cytosolic thiols exist, annoyingly for the model but mercifully for the neuron
Aminochrome, normal detox ~1–10 s ~15–45 μm Can spread across a local axonal/dendritic neighborhood
Aminochrome, P187S / weak NQO1 ~5–30+ s ~45–100 μm More likely to reach neighboring local compartments, still not long-range
H₂O₂, intracellular ~0.1–10 s depending scavenging ~1–100 μm Can signal/damage across local microdomains
H₂O₂, extracellular/low scavenging longer ~100+ μm Can spread to neighboring cells or nearby glia

Approximate survival fraction after distance (x), using (e^{-x/L}):

Species/model Survives 10 μm Survives 100 μm Survives 1 mm
DA-o-quinone, cytosolic (L≈1.4 μm) ~0.08% ~zero zero
DA-o-quinone, low-thiol edge (L≈4.5 μm) ~11% ~zero zero
Aminochrome, normal (L≈32 μm) ~73% ~4% ~zero
Aminochrome, P187S-ish (L≈63 μm) ~85% ~20% ~0.00001%
H₂O₂, cytosol (L≈40 μm) ~78% ~8% ~zero
H₂O₂, extracellular (L≈160 μm) ~94% ~54% ~0.2%

So: dopamine-o-quinone is ultra-local. Aminochrome is local-to-neighborhood. H₂O₂ is local-to-regional. None of these are meaningful soma-to-distal-axon travelers.

For plain diffusion time alone, ignoring reaction:

Distance DAQ/aminochrome at (D≈200 μm²/s) H₂O₂ at (D≈2000 μm²/s)
10 μm ~0.25 s ~0.025 s
100 μm ~25 s ~2.5 s
1 mm ~42 min ~4 min
1 cm ~69 h ~7 h
4 m ~1,270 years ~127 years

A human SNc dopamine neuron has been estimated to have >1 million synapses and axonal length exceeding 4 m, which is exactly the kind of biological architecture you would design if your grant proposal were “how do we make maintenance impossible.” (Frontiers)

4. Does AMPH increase H₂O₂ too?

Yes. Amphetamine can redistribute dopamine from vesicles toward cytosol and promote dopamine efflux, while methylphenidate mainly blocks reuptake. More cytosolic dopamine means more substrate for both auto-oxidation and MAO metabolism. MAO metabolism of monoamines produces the corresponding aldehyde, ammonia, and H₂O₂; acute d-amphetamine has been reported to stimulate H₂O₂ production in mouse tissues. (PMC)

Using our previous 5 mg Adderall anchor:

Quantity per 5 mg Adderall use Rough estimate
Extra reactive DAQ/aminochrome-equivalent formed ~0.057 nmol
Extra H₂O₂ from extra dopamine MAO turnover ~1–4 nmol
H₂O₂ molecules vs quinone-equivalent molecules ~20–70× more

But H₂O₂ is not automatically “worse” just because there are more molecules. H₂O₂ is buffered by peroxiredoxins, GPx, catalase, thioredoxin, GSH systems, and it is often part of signaling. DAQ/aminochrome are more directly protein-adduct-forming. Tiny distinction, huge consequences, naturally.

5. What happens in boutons and spines?

For a small compartment connected by a neck/shaft, the escape time is roughly:

[
\tau_{\text{escape}} \approx \frac{V L}{D A}
]

where (V) is compartment volume, (L) is neck length, and (A) is neck cross-sectional area.

The fraction that reacts before escaping is roughly:

[
f_{\text{react-before-escape}}
\approx
\frac{k\tau}{1+k\tau}
]

Dendritic spines commonly have submicron heads, necks around ~100 nm wide and ~1 μm long, with thin, stubby, and mushroom forms; long thin necks reduce diffusional coupling with the dendrite, and mushroom spines retain molecules/receptors more effectively than stubby spines. (Frontiers)

Geometry-based estimate

Compartment Escape time for small soluble molecule DA-o-quinone local reaction before escape Aminochrome local reaction before escape Interpretation
Small axonal bouton/varicosity ~1–5 ms ~10–80% <1% DAQ partly local, aminochrome escapes into nearby axon
Large bouton ~20–100 ms ~70–99% ~0.1–2% DAQ mostly hits bouton-local targets
Spiny/complex bouton variable, often more constrained high if local DAQ made there low-to-moderate high risk if dopamine cycling/mitochondria are active
Stubby spine <1–10 ms low-to-moderate if generated inside low quickly equilibrates with dendrite
Thin/small spine ~10–100 ms moderate-to-high if generated inside low local DAQ can hit PSD/actin proteins if produced there
Mushroom spine, narrow neck ~0.3–2 s ~near-total if generated inside ~2–30% strongest compartmental trapping

Important caveat: dopamine-o-quinone/aminochrome are mainly generated inside dopaminergic presynaptic terminals, not inside postsynaptic glutamatergic spine heads, unless dopamine oxidizes extracellularly or enters that compartment. So mushroom spine trapping matters more for H₂O₂/redox signaling and local postsynaptic oxidative chemistry than for presynaptic cytosolic DAQ.

6. Do distal parts get less than proximal parts?

From a proximal source, yes. Absolutely. Dopamine-o-quinone from soma/proximal axon is gone within microns. Aminochrome might make it tens of microns. H₂O₂ can go farther, but still not millimeters-to-centimeters in a meaningful intracellular way.

But in amphetamine exposure, the source term is not just proximal:

[
S(x,t) \text{ is high wherever DAT/VMAT2/dopamine handling is high}
]

That means distal dopaminergic boutons produce their own DAQ/aminochrome/H₂O₂ locally. So distal terminals can have higher actual local damage than proximal parts, not because toxins arrive there, but because dopamine turnover and vesicular/cytosolic dopamine stress happen there.

This is the key correction:

Question Answer
Do quinones diffuse from soma to distal axon? No, essentially zero
Do distal boutons experience quinone load? Yes, generated locally
Does H₂O₂ diffuse farther than quinones? Yes, much farther
Does P187S make distal exposure more long-ranged? Somewhat for aminochrome, not much for DA-o-quinone
Does AMPH increase local distal terminal stress? Yes, especially where dopamine handling is dense

7. What does P187S change in transport?

NQO1 is a two-electron quinone reductase and part of cellular adaptation to quinone/redox stress. NQO1 Pro187Ser / C609T reduces activity; homozygous TT carriers have been reported to retain only ~2–4% of wild-type quinone reductase activity. (PMC)

Transport-wise:

Species P187S effect
Dopamine-o-quinone modest transport effect, because fast GSH/protein-thiol chemistry dominates before NQO1 matters much
Aminochrome bigger effect: lower NQO1 means longer lifetime, more chance to diffuse tens of microns
H₂O₂ not directly NQO1-controlled; affected indirectly if quinone stress damages mitochondria/GPx/PRX systems

Rule of thumb:

[
L \propto \sqrt{\frac{1}{k}}
]

So if P187S reduces effective aminochrome clearance by , the diffusion length rises by about:

[
\sqrt{4}=2×
]

That does not turn aminochrome into a long-range axonal traveler. It turns a ~30 μm problem into a ~60 μm problem, which is still very relevant inside a dense terminal arbor.

8. Where are the weakest detox/repair zones?

Most likely vulnerability ranking:

Rank Location Why vulnerable
1 Distal dopaminergic axonal boutons/varicosities high dopamine handling, high DAT/VMAT2 flux, small volume, local mitochondria demand, local DAQ/H₂O₂ generation
2 Thin terminal branches / branch points high surface-area burden, transport bottlenecks, energy stress, local failure can disconnect multiple downstream terminals
3 Large active boutons more vesicles/DA cycling, more mitochondria, more release machinery; better buffered but more source production
4 Mushroom spines receiving strong input narrow necks trap local redox effects; more important for stable synaptic weights
5 Small/thin spines low reserve, but more replaceable; damage may prune plastic capacity
6 Soma/proximal dendrite better repair/proteostasis access, but damage here has global consequences if severe

The most dangerous pattern is not “one molecule diffuses far.” It is:

[
\text{local dopamine stress}
\rightarrow
\text{DAQ/aminochrome/H₂O₂}
\rightarrow
\text{mitochondrial or VMAT2/DAT damage}
\rightarrow
\text{more cytosolic dopamine}
\rightarrow
\text{more local oxidation}
]

That feedback loop matters more in distal boutons than in the soma.

9. Long-range vs short-range damage: which matters more?

For carrying a dopamine signal, damage in long-range distal axonal boutons matters more per event than damage in most proximal compartments.

Why:

  1. Dopamine signal output is mostly terminal/bouton function: vesicle loading, release, DAT recycling, mitochondrial ATP, calcium handling.
  2. Distal axonal arbor is huge and energetically expensive in human SNc dopamine neurons.
  3. Local bouton damage can cause functional dropout without immediately killing the soma.
  4. Axonal terminal dysfunction often behaves like a “dying-back” problem: distal output degrades before the whole neuron dies.

For neuroplasticity, postsynaptic spine damage matters too, but differently:

Spine type Damage consequence
Thin/small spines may reduce flexibility/exploration; more likely to be pruned/replaced
Mushroom spines more likely to affect stable learned synaptic weights
Large spines with narrow necks more local trapping, slower detox equilibration
Stubby spines less chemical isolation, more exchange with shaft

So: long-range axonal bouton damage matters more for dopamine transmission. Mushroom-spine damage matters more for learned circuit weights. Soma damage matters more only when it hits global repair/mitochondrial/protein-production capacity.

10. Practical model conclusion

For AMPH/P187S:

Species Main danger zone Travels to distal neuron parts? Generated locally in distal parts?
Dopamine-o-quinone same bouton/microdomain No Yes
Aminochrome local axon/dendrite neighborhood, ~10–100 μm Not long-range Yes
H₂O₂ mitochondria, cytosol, extracellular neighborhood Locally, yes; long-range, no Yes

The clean estimate:

~80–99.999% of dopamine-o-quinone reacts before leaving the local bouton/spine-scale microdomain.
Aminochrome can spread to nearby boutons/shaft segments, roughly tens of microns, and P187S may roughly double that spread length in bad cases.
H₂O₂ can spread much farther than quinones, and AMPH likely increases it through cytosolic dopamine metabolism by MAO.

So the vulnerable place is not “distal because proximal toxins diffuse there.” It is:

distal dopaminergic boutons because they are tiny, dopamine-loaded, energy-stressed, repair-limited local factories for the reactive species themselves.

A stupidly elegant design, if the goal was making the most important parts of dopamine signaling also the parts with the least margin.

Yes, but the answer is less “superdiffusive quinone apocalypse” and more “tiny reactive things die locally while boring Brownian diffusion does most of the work.” Superdiffusion matters for vesicles, mitochondria, protein aggregates, and damaged cargo, not much for free dopamine-o-quinone or aminochrome before they react.

Core transport model

Use anomalous diffusion:

[
\langle r^2(t)\rangle = 2d_{\text{eff}}K_\alpha t^\alpha
]

where:

Regime MSD exponent (\alpha) Walk dimension (d_w = 2/\alpha) Meaning
Subdiffusion ~0.6–0.95 ~2.1–3.3 Crowding, trapping, spine necks, organelles
Brownian diffusion 1.0 2.0 Normal free small-molecule diffusion
Superdiffusion ~1.2–1.8 ~1.1–1.7 Active/motor-driven cargo, cytoskeletal transport
Ballistic transport 2.0 1.0 Nearly straight motor/advection movement

For free dopamine-o-quinone and aminochrome, use Brownian or mildly subdiffusive transport, not superdiffusion. Intracellular active transport is real, but it applies mainly to cargos such as vesicles, organelles, proteins, mRNA complexes, and aggregates. Axons show stronger superdiffusive active transport than dendrites in some cargo-tracking models, while dendrites look more like weakly directed random walks. Free reactive quinones do not politely board a kinesin bus. They react first. (PMC)

Effective geometry matters more than “cell-wide diffusion”

A molecule’s transport dimension changes by compartment:

Compartment Effective spatial dimension for free metabolite
Cytosol inside soma / bouton / spine head 3D
Long thin axon or dendrite after radial mixing quasi-1D
Membrane / lipid phase 2D
Spine head plus narrow neck 3D reservoir + 1D bottleneck
Extracellular brain space tortuous 3D

This matters because the affected “footprint” scales roughly as:

[
\text{affected region} \propto L^{d_{\text{eff}}}
]

So if P187S or low detox capacity doubles aminochrome’s diffusion length (L), the footprint rises about:

Geometry If (L) doubles
1D axon shaft ~2× longer reach
2D membrane ~4× affected area
3D bouton/ECS/cytosol ~8× affected volume

That is the nasty nonlinear part. Not because molecules become magical, just because geometry is a smug little tyrant.

Relative transport of “bad dopamine” species

Approximate intracellular values, assuming free small-molecule diffusion (D \sim 100–300 \mu m^2/s) after cytoplasmic hindrance. Cytoplasm can slow diffusion several-fold relative to water due to crowding/excluded volume. (PMC)

Species Main source Dominant transport Effective reach before reaction/detox Superdiffusive?
Hydroxyl radical ·OH Fenton chemistry from H₂O₂ + iron/copper none, instant local reaction nm-scale No
Superoxide O₂·⁻ mitochondria, redox cycling local diffusion, SOD conversion sub-μm to few μm No
Dopamine-o-quinone / DAQ dopamine auto-oxidation Brownian/subdiffusive ~1–10 μm usually; up to ~30–40 μm only in unrealistically low-thiol conditions No
Aminochrome DAQ cyclization Brownian/subdiffusive ~20–100 μm; longer if NQO1/GSH detox weak No
5,6-indolequinone / neuromelanin intermediates aminochrome downstream local binding/polymerization local, μm-scale to tens μm No
DOPAL MAO dopamine metabolism Brownian, membrane-permeable-ish aldehyde tens to hundreds μm if ALDH detox is poor No
H₂O₂ MAO, mitochondria, redox cycling Brownian diffusion + membrane crossing intracellular: few–tens μm; extracellular: ~100 μm class No, but it is the best “volume” diffuser here
4-HNE / lipid aldehydes lipid peroxidation downstream of ROS membrane + cytosol diffusion tens–hundreds μm, sometimes farther Not usually; can spread by membranes/fluids

Dopamine-o-quinone cyclizes toward aminochrome at about 0.15 s⁻¹, but in real cytosol it also reacts with glutathione, cysteine, and protein thiols. Dopamine-derived quinones can modify protein sulfhydryls, while aminochrome is more stable and therefore more spatially spreadable. (PMC)

Brownian vs superdiffusive contribution

For free DAQ/aminochrome, I would assign transport weight like this:

Species Brownian/subdiffusive contribution Superdiffusive contribution
Dopamine-o-quinone ~99%+ ~0% before reaction
Aminochrome ~95–99% ~0–5%, only indirectly if bound/adducted to mobile cargo
DOPAL ~90–99% small indirect cargo/adduct contribution
H₂O₂ ~99% diffusion/reaction ~0%
4-HNE/lipid aldehydes mostly diffusion + membrane partitioning possible indirect transport in membranes/vesicles

The important exception: once a quinone has already reacted with a protein, vesicle, mitochondrion, or α-synuclein complex, the damaged cargo can be moved by active transport. But that is not “dopamine-o-quinone spreading.” That is the molecular equivalent of shipping the crime scene after the crime has already happened.

Intracellular vs extracellular transport

Intracellular

Inside neurons, the relevant equation is reaction-diffusion:

[
\frac{\partial C}{\partial t}=D\nabla^2C-kC+S(x,t)
]

where (k) is detox/reaction/removal. The diffusion length is:

[
L \approx \sqrt{\frac{D}{k}}
]

Intracellularly:

Factor Effect
High GSH/protein thiols Shortens DAQ lifetime, increases local adducting
NQO1 / GSTM2 / ascorbate systems Reduce quinone persistence
Crowding/organelles Mild subdiffusion
Axon/dendrite geometry Converts long-range spread into quasi-1D diffusion
Spine/bouton necks Trap species locally
Proteasome/autophagy Determines whether adduct damage persists

NQO1 P187S mainly affects quinone clearance, especially aminochrome-like quinones. Homozygous P187S/TT has been reported at only about 2–4% of wild-type quinone reductase activity, and NQO1 has been implicated in protecting against aminochrome-induced α-synuclein oligomerization/neurotoxicity. (PMC)

Extracellular

Extracellular brain space is not open water. It is a narrow, tortuous 3D maze with volume fraction around ~0.2 and tortuosity around ~1.6, so effective diffusion is slowed roughly by (D^* = D/\lambda^2), about a 2.5× reduction for many small solutes. (PubMed)

Extracellularly:

Factor Effect
Tortuosity Slows diffusion
Larger available space Dilutes concentration
Lower cytosolic GSH Some reactive species may persist longer chemically
Cell surfaces / ECM / proteins Provide reaction targets
DAT/uptake/astrocytes Remove dopamine and metabolites
Interstitial/glymphatic flow Too slow to matter for DAQ/aminochrome, relevant for stable metabolites over hours

There is debate about diffusion versus advection in brain solute transport, but even models supporting human brain-wide advection estimate flow speeds on the order of 1–9 μm/min. That is irrelevant for DAQ and mostly irrelevant for aminochrome, because they react on seconds-to-minutes timescales. It matters more for stable metabolites, extracellular waste, and long-duration clearance. (Springer)

Does AMPH increase H₂O₂?

Yes, plausibly. Dopamine metabolism by MAO produces DOPAL + H₂O₂, and dopamine oxidation can also feed ROS chemistry. A mouse study reported that acute d-amphetamine stimulated H₂O₂ production in studied tissues. Translation to low-dose therapeutic human exposure is not clean, because apparently biology refuses to be a spreadsheet, but directionally: AMPH can increase H₂O₂ load. (Springer)

H₂O₂ is much more transport-capable than DAQ/aminochrome. In vivo brain-tissue work estimated extracellular H₂O₂ effective diffusivity at 2.5 × 10⁻⁵ cm²/s, with enough persistence to diffuse over roughly 100 μm in extracellular space. That makes H₂O₂ a local volume redox signal, unlike DAQ, which is basically a local vandal. (PMC)

Distance estimates

Using rough diffusion-reaction lengths:

Species Intracellular reach Extracellular reach Long-range neuron transport?
DAQ ~1–10 μm ~few–tens μm if not immediately scavenged No
Aminochrome ~20–100 μm ~30–150 μm maybe No meaningful soma-to-distal transport
H₂O₂ ~3–50 μm intracellular ~100 μm extracellular Local/regional, not cm-scale
DOPAL ~30–300 μm, context-dependent likely similar or farther if not metabolized Local-to-regional
4-HNE ~tens–hundreds μm can affect neighboring cells More spreadable than dopamine quinones
DOPAC/HVA much farther, but mostly non-adducting clearance/metabolite transport Yes, but not the dangerous chemistry

So, from a proximal source:

Distance from source DAQ Aminochrome H₂O₂
1 μm substantial substantial substantial
10 μm much DAQ gone much survives much survives
100 μm DAQ essentially gone partial survival possible partial survival likely
1 mm gone effectively gone tiny to none intracellularly
cm-scale axon zero zero zero as a reactive point-source signal

Distal axons and boutons are not damaged because DAQ travels there from the soma. They are vulnerable because they generate their own DAQ/aminochrome/H₂O₂ locally during dopamine handling.

Boutons and spines

Structure Transport/damage implication
Small dopaminergic bouton small volume, high dopamine flux, high local concentration spikes; weak reserve
Large bouton more buffer volume, but more vesicles/mitochondria/source production
Thin axonal branch quasi-1D, limited repair traffic, vulnerable to local mitochondrial/proteostasis stress
Small/thin spine small volume, high concentration from local redox events, more replaceable
Mushroom spine bigger volume but narrow neck traps molecules longer; damage may matter more for stable synaptic weights
Stubby spine less trapping, faster exchange with dendrite

DAQ hits within the same bouton/spine-scale microdomain. Aminochrome can reach neighboring shaft/bouton regions. H₂O₂ and lipid aldehydes are the ones that can plausibly influence nearby spines, glia, and adjacent microdomains.

Where detox/repair is weakest

The most vulnerable zones are probably:

  1. Distal dopaminergic boutons/varicosities: high dopamine handling, mitochondria, DAT/VMAT2 cycling, small volume.
  2. Thin terminal axons and branch points: transport bottlenecks, low redundancy.
  3. Mitochondria-rich presynaptic regions: H₂O₂/DOPAL/DAQ converge there.
  4. Mushroom spine heads with narrow necks: trapping and stable synaptic-weight consequences.
  5. Long-range axonal arbor regions: damage matters because dopamine output is terminal-distributed.

Damage to distal axonal boutons matters more for dopamine signal carrying. Damage to mushroom spines matters more for stored circuit weights / learned synaptic structure. Soma damage matters most only when it impairs global protein synthesis, mitochondrial supply, or repair capacity. The soma is the factory; the distal bouton is the overworked retail location with bad lighting and no staff.

Ultraweak photon emissions?

Yes, likely in principle. Ultraweak photon emission comes from electronically excited species generated during oxidative metabolism, especially ROS-linked lipid/protein/nucleic-acid oxidation. Biological UPE is typically extremely faint, often discussed around 10–10⁴ photons/s/cm² depending on tissue and stress state, detectable only with sensitive photomultipliers or cooled cameras, not your eyes, because human eyeballs remain disappointingly analog. (ScienceDirect)

There is direct animal evidence that methamphetamine increases both ROS and UPE in rat brain regions. That is methamphetamine, not prescribed low-dose amphetamine, so I would not copy-paste the magnitude. But mechanistically, if AMPH increases dopamine turnover, H₂O₂, mitochondrial stress, or lipid peroxidation, it should also slightly increase UPE. (ScienceDirect)

My estimate:

Condition UPE change
Normal metabolic activity baseline ultraweak emission
Therapeutic-low AMPH, rested/fed probably small increase
AMPH + sleep loss / overheating / inflammation / high oxidative stress larger increase
Methamphetamine/high-dose stimulant models measurable increase in animal studies

But UPE is not a meaningful transport route for DAQ/aminochrome toxicity. It is mostly an optical exhaust signal from oxidative chemistry, not a biochemical delivery truck.

Bottom line

Free dopamine-o-quinone is mostly local Brownian/subdiffusive chemistry, reacting within microns.

Aminochrome is more spreadable, reaching tens of microns, maybe ~100 μm in weak-detox/P187S-like conditions, but still not long-range.

H₂O₂ and lipid aldehydes are the major longer-range redox spreaders.

Superdiffusion matters after damage has occurred, when adducted proteins, damaged vesicles, mitochondria, or aggregates are transported as cargo. It does not rescue free DAQ/aminochrome from their tragic little reactive lifetimes.

So the real spatial risk map is:

[
\text{local dopamine handling sites}
\rightarrow
\text{local DAQ/aminochrome}
\rightarrow
\text{nearby protein/mitochondrial damage}
\rightarrow
\text{H₂O₂ / lipid aldehyde spread}
\rightarrow
\text{cargo/proteostasis consequences transported later}
]

Distal neuron parts get less from proximal sources, but distal dopaminergic boutons can still be the most vulnerable because they are local source sites with poor margins. Chemistry, having no compassion, attacks where the signal is actually made.

It seems that for some people with a certain subtype of ADHD/ADD that mitochondrial dysfunction could be the leading cause. Additionally, I think for most people addressing mitochondrial dysfunction and ROS/metabolic cleanup will be a useful ancillary in addition to ADHD stimulant medication to prevent negative side effects.

Myself I use 2.5-5g of NAC daily for glutathione antioxidant support, 40mg nightly of telmisartan to control blood pressure, exercise regularly, focus on sleep optimization and a number of other interventions to try and offset harm from dexamphetamine ADHD medication.

I’m increasingly interested in trialling SS-31, as well as intramuscular glutathione and ubiquinol.

Methylene blue might also be useful here if it didn’t have MAOI effects which can be an issue with dexamphetamine.

Beta blockers might be useful if it weren’t for my negative interactions with them due to asthma.

I’ve also come across some disturbing data that (some?) beta blockers impair melatonin production by 50%:

“Long-term beta-blockers administration decrease endogenous melatonin synthesis to 50% increasing the risk for insomnia and vascular brain damage”
The effect of long-term beta-blockers on melatonin secretion, sleep quality, and vascular brain damage Source: Europe PMC

Propranolol and atenolol decreased nocturnal melatonin production, but carvediol did not appear to:

“These data show that only the specifically beta-blocking (S)-enantiomers of propranolol and atenolol decrease the nocturnal production of melatonin whereas the non-beta-blocking (R)-enantiomers have no effect. Unexpectedly, (R,S)-carvedilol which inhibits both alpha- and beta-adrenoceptors does not decrease melatonin production.”
# Influence of beta-blockers on melatonin release Source: Influence of beta-blockers on melatonin release - PubMed

In light of @Beth stating that SS-31 peptide has helped her “ADD/ADHD” (in this thread: Hazel Szeto, SS-31 peptide, the World's First FDA-Approved Mitochondria-targeted Drug (Longevity Summit, 2025)) I did a ChatGPT prompt on this to find out more information and wanted to place it here in this ADHD specific thread":

ADHD, stimulants, oxidative stress, and where SS-31 actually fits

There’s a growing pattern in both literature and anecdote:

  • ADHD is not just neurotransmitter imbalance
  • It often involves oxidative stress, inflammation, and mitochondrial dysfunction
  • Stimulants, while effective, increase dopamine turnover, which can amplify oxidative load

This creates a loop:

dopamine signaling → ROS generation → mitochondrial stress → worse neuronal efficiency → more reliance on stimulation

There’s decent evidence that oxidative stress and inflammation are part of ADHD biology, and that antioxidant strategies are being explored as adjuncts


Where common “ancillaries” fit (NAC, glutathione, ALA)

Most of the standard add-ons people use with stimulants sit in the same layer:

1. NAC (N-acetylcysteine)

  • Precursor to glutathione (GSH)
  • Reduces ROS and inflammation
  • Modulates glutamate and indirectly dopamine

Mechanistically:

  • protects dopamine neurons from oxidative damage
  • can normalize redox balance and mitochondrial function
  • may reduce stimulant-induced neurotoxicity

Important nuance:

  • NAC often smooths stimulant effects
  • sometimes reduces intensity or “edge”
  • improves stability rather than raw drive

2. Glutathione (including injectable)

  • Master intracellular antioxidant
  • Buffers oxidative stress directly

Relevance:

  • ADHD and stimulant use both intersect with GSH depletion states
  • higher brain glutathione is associated with better sustained effort and performance (human + animal data)

3. Alpha-lipoic acid (ALA)

  • Redox-active antioxidant
  • Regenerates glutathione, vitamin C, vitamin E
  • Supports mitochondrial enzymes

Effect profile:

  • broad oxidative stress reduction
  • less targeted than NAC or SS-31
  • sits somewhere between systemic antioxidant and mitochondrial support

The key limitation of all of the above

They mostly do this:

clean up oxidative stress after it’s produced

They:

  • scavenge ROS
  • replenish antioxidant systems
  • reduce inflammation downstream

But they do not directly fix the source of the problem, which is:

inefficient mitochondrial electron transport → electron leak → ROS generation


Where SS-31 is fundamentally different

SS-31 (elamipretide) operates one level upstream.

Instead of acting as a general antioxidant, it:

  • binds cardiolipin in the inner mitochondrial membrane
  • stabilizes electron transport chain structure
  • reduces electron leak at the source
  • increases ATP production

This leads to:

  • ↓ ROS generation (not just cleanup)
  • ↑ mitochondrial efficiency
  • ↓ inflammatory signaling (IL-6, TNF-α reductions seen in models)
  • ↑ synaptic function and plasticity

Framing the difference (this is the important part)

NAC / Glutathione / ALA:

“Damage control”

  • buffer oxidative stress
  • reduce downstream damage
  • stabilize neurotransmission indirectly

SS-31:

“Infrastructure repair”

  • prevents ROS generation at the mitochondrial level
  • restores energy production capacity
  • improves signal fidelity upstream

Why SS-31 could feel uniquely effective (in some people)

If someone’s ADHD is significantly driven by:

  • mitochondrial inefficiency
  • high ROS burden
  • inflammation-linked dysfunction

then:

  • NAC = partial improvement (less noise)
  • SS-31 = removal of the bottleneck

This can produce the kind of anecdote you mentioned:

“only thing besides stimulants that actually worked”

Because it’s not compensating for dysfunction, it’s removing a constraint.


How this ties into stimulant use

Stimulants:

  • increase dopamine signaling
  • increase neuronal firing demand
  • increase oxidative stress (dopamine metabolism → ROS)

Antioxidant stack (NAC, GSH, ALA):

  • reduces collateral damage
  • improves tolerability
  • may smooth side effects

SS-31:

  • potentially improves the system’s ability to handle the increased demand

Putting it together: layered model

Think of it like this:

Layer 1: neurotransmitters

  • stimulants (amphetamine, methylphenidate)

Layer 2: redox buffering

  • NAC
  • glutathione
  • ALA

Layer 3: mitochondrial structure/function

  • SS-31

Practical implication

The interesting strategy isn’t choosing one, it’s understanding the stack:

  • NAC / GSH / ALA → reduce damage and stabilize signaling
  • SS-31 → increase capacity and efficiency

That’s:

buffering + repair


Caveats (important)

  • No clinical evidence that SS-31 treats ADHD
  • Most data is from:
    • mitochondrial disease
    • aging
    • neuroinflammation models
  • Antioxidants like NAC:
    • sometimes blunt stimulant intensity
    • effects vary widely by individual
  • SS-31:
    • still experimental in this context
    • long-term cognitive effects unknown

Bottom line

There’s a clean mechanistic hierarchy:

  • NAC / glutathione / ALA
    → reduce oxidative stress and protect neurons
  • SS-31
    → improves mitochondrial function at the source

If ADHD symptoms are partly driven by energy limitation and oxidative stress, then:

SS-31 has a plausible path to producing stronger, more “foundational” effects than standard antioxidant adjuncts

But it’s likely:

subtype-specific, not universal